Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and content measurement, audience insights and product development. List of Partners (vendors)

The first daily pill for treating endometriosis symptoms has been approved for use on the NHS in England and Wales - but only for patients who have tried all other options. Endometriosis affects 1.5 million women in the UK, causing pain and extreme tiredness as a result of tissue similar to the womb lining growing elsewhere in the body.

Hoorah for some positive women's health news! A new endometriosis pill has been made available on the NHS in England, in what's being a called a “first-of-its-kind” step forward in treating the debilitating disease.

The National Health Service (NHS) in England has approved Gedeon Richter’s Ryeqo (relugolix + estradiol + norethisterone), the first long-term pill available for endometriosis, marking a significant breakthrough in treatment.

A new combination pill, relugolix–estradiol–norethisterone, has been approved for treating endometriosis on the NHS. This marks the first long-term, daily oral treatment for the condition, offering a significant advancement in endometriosis management.

A daily pill has been approved by NICE for treating some women with endometriosis after initially being rejected.

A transformational new pill for treating endometriosis has been approved for use on the NHS across England. The new tablet, called relugolix-estradiol-norethisterone, has been approved by the drug regulator, National Institute for Health and Care Excellence (Nice).

The new drug, called relugolix-estradiol-norethisterone, is a combination pill that blocks specific hormones that contribute to endometriosis, while also providing necessary hormone replacement